Abstract
Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
| Language | English |
|---|---|
| Pages | 55-62 |
| Number of pages | 8 |
| Journal | European Journal of Cancer |
| Volume | 80 |
| DOIs | |
| Publication status | Published - 1 Jul 2017 |
Fingerprint
Keywords
- non–clear cell RCC
- chromophobe RCC
- metastatic
- anti-angiogenic
- VEGF
- mTOR
Cite this
}
Metastatic chromophobe renal cell carcinoma treated with targeted therapies : a Renal Cross Channel Group study. / Colomba, Emeline; Le Teuff, Gwénaël; Eisen, Tim; Stewart, Grant D.; Fife, Kate; Larkin, James; Biondo, Andrea; Pickering, Lisa; Srinivasan, Anandagopal; Boyle, Helen; Derosa, Lisa; Sternberg, Cora N.; Recine, Federica; Ralph, Christy; Saldana, Carolina; Barthélémy, Philippe; Bernhard, Jean Christophe; Gurney, Howard; Verhoest, Gregory; Vauleon, Elodie; Bigot, Pierre; Berger, Julien; Pfister, Christian; Gravis, Gwenaelle; Rodier, Jean-Michel; Culine, Stéphane; Caty, Armelle; Rolland, Frederic; Priou, Franck; Escudier, Bernard; Albiges, Laurence.
In: European Journal of Cancer, Vol. 80, 01.07.2017, p. 55-62.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Metastatic chromophobe renal cell carcinoma treated with targeted therapies
T2 - European Journal of Cancer
AU - Colomba, Emeline
AU - Le Teuff, Gwénaël
AU - Eisen, Tim
AU - Stewart, Grant D.
AU - Fife, Kate
AU - Larkin, James
AU - Biondo, Andrea
AU - Pickering, Lisa
AU - Srinivasan, Anandagopal
AU - Boyle, Helen
AU - Derosa, Lisa
AU - Sternberg, Cora N.
AU - Recine, Federica
AU - Ralph, Christy
AU - Saldana, Carolina
AU - Barthélémy, Philippe
AU - Bernhard, Jean Christophe
AU - Gurney, Howard
AU - Verhoest, Gregory
AU - Vauleon, Elodie
AU - Bigot, Pierre
AU - Berger, Julien
AU - Pfister, Christian
AU - Gravis, Gwenaelle
AU - Rodier, Jean-Michel
AU - Culine, Stéphane
AU - Caty, Armelle
AU - Rolland, Frederic
AU - Priou, Franck
AU - Escudier, Bernard
AU - Albiges, Laurence
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
AB - Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
KW - non–clear cell RCC
KW - chromophobe RCC
KW - metastatic
KW - anti-angiogenic
KW - VEGF
KW - mTOR
UR - http://www.scopus.com/inward/record.url?scp=85019953522&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2017.03.011
DO - 10.1016/j.ejca.2017.03.011
M3 - Article
VL - 80
SP - 55
EP - 62
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -